The Pritzker Organization invests in AI-driven Systems Oncology

Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round.

The new capital will be used for investing in discovery research and pre-clinical development to evolve Systems Oncology’s pipeline of cancer therapeutics.

The therapeutic insights generated by Systems Oncology are applied to develop therapeutic programs. The company’s ExpansiveAI discovery engine is said to enable scientists to integrate and translate big data from multiple scientific sources into intelligently linked scientific knowledge, which makes it possible to uncover therapeutic opportunities.

Joseph Gleberman – Managing Director of The Pritzker Organization said: “We are very excited about the potential for Systems Oncology’s combination of leading-edge AI and outstanding clinical expertise to produce novel cancer therapies.”

Systems Oncology secures investment from The Pritzker Organization. Image courtesy of cooldesign at FreeDigitalPhotos.net.

The ExpansiveAI discovery engine is a cognitive computing platform that integrates and connects multiple different types of data into multidimensional models, which is said to enable exceptional scale and efficiency in applying machine learning to mine trillions of biomedical relationships. The artificial intelligence drug discovery engine is said to help Systems Oncology to explore a number of therapeutic opportunities.

Dr. Spyro Mousses – CEO of Systems Oncology said: “We are honored by the investment from The Pritzker Organization and look forward to them joining us with a seat on our Board of Directors.

“TPO’s investment is a prestigious recognition for the potential SO has to transform drug discovery and development with AI. They bring a wealth of experience investing in and growing companies and will help us continue to grow for years to come and fulfill our commitment to bring forward breakthrough oncology therapeutics for unmet patient needs.”